Cyclopharm Limited · ASX:CYC
Cyclopharm — FY2008 Earnings Presentation
15 slides from Cyclopharm's earnings presentation, Mar 3, 2009
Slide 1: Cyclopharm Limited Financial Year 2008
For personal use only Cyclopharm Limited FINANCIAL YEAR 2008 3 MARCH 2008 90303
Slide 2: Disclaimer
Disclaimer For personal use only Certain views expressed here contain information derived from publicly available sources that have not been independently verified. The presentation includes certain statements, estimates and projections with respect to the anticipated future financial performance of
Slide 3: Highlights - Financial Year 2008
Highlights ‐ Financial Year 2008 For personal use only 9 Profits up 55% and EPS up 49% 9 Net cash flow up $3.0 million 9 Equity and financing secured for growth 9 FDA progressing 9 New Technegas applications in the pipeline 9 PET Nuclear pharmacy plan on track 9 Government funding approvals for PET
Slide 4: Technegas Global footprint
Technegas Global footprint For personal use only • Technegas is sold in 53 countries across the world • Over 2,200,000 patient studies since 1988 • 167,000 patient studies conducted in 2008 • 1,120 Technegas generators sold globally Asia • Patents in 36 countries Europe, Pacific 15% Middle Americas
Slide 5: 2008 Financials
For personal use only 2008 Financials Fi i l 5
Slide 6: Profit & Loss
Profit & Loss For personal use only 9Net profit after tax increases 55% • Technegas related sales revenue was down on the prior comparative period, 2008 2007 gross profit margins and profitability $ $ CONTINUING OPERATIONS improved due to a shift in sales mix Total revenue 10,937,646 11,229,630 and
Slide 7: Sales revenue - Segmental Review
Sales revenue ‐ Segmental Review For personal use only 9 Consolidated profit margins improve Patient Administration Sets (PAS) • Targeting T ti margin i improvement i t in i 2008 • PAS revenue up 11.9% to $9.3 m • PAS volumes down 5% TechnegasPlus • 2007 200 iintroductory d offer ff not extended d d
Slide 8: Sales revenue Half year comparison
Sales revenue Half year comparison For personal use only 9 Historical Trend – strong second half results continue 8
Slide 9: Strong Balance Sheet
Strong Balance Sheet For personal use only 9 Funding secured for strategic growth • $3.18m raised through fully subscribed rights issue (before Balance Sheet Summary 2008 2007 issue costs off $0.15m) $ ) $ $ • Debt facility increased to $6.45m Total Current Assets 12,443,583 7,763,729 Total Non-curr
Slide 10: Robust Operating Cash flow
Robust Operating Cash flow For personal use only 9 Net cash flow increases $3.0m over prior year • The improvement in operating cash flows resulted from reduced expenses 2008 2007 and favourable currency movements $ $ Net cash flows from • Higher inventory balance driven by operating activities 1,48
Slide 11: Business Objectives 2009
For personal use only Business B i Obj Objectives i 2009 11
Slide 12: Business Overview 2009: Technegas
Business Overview 2009 Technegas For personal use only New Drug Application (NDA) • NDA submitted December 2008 • Application withdrawn February 2009 based on initial FDA feedback • Meeting with FDA targeted late March 2009 to agree path forward New Indications for Technegas • Currently in discussio
Slide 13: Business Overview 2009: Molecular Imaging
Business Overview 2009 Molecular Imaging For personal use only Macquarie University Private Hospital (MUPH) • Project on track • Sales forecasted to commence December 2009 • Capacity increasing through 2010 Kensington • Shell construction to commence mid mid‐2009 2009 • Commercial fit‐out to schedul
Slide 14: Conclusion
For personal use only C l i Conclusion 14
Slide 15: Highlights - Financial Year 2008
Highlights ‐ Financial Year 2008 For personal use only 9 Profits up 55% and EPS up 49% 9 Net cash flow up $3.0 million 9 Equity and financing secured for growth 9 FDA progressing 9 New Technegas applications in the pipeline 9 PET Nuclear pharmacy plan on track 9 Government funding approvals for PET